Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Q2 Holdings reported FY2025 revenue of $794.8 million, Q1 2026 revenue of $216.5 million, FY2025 operating cash flow of $201.5 million and Q1 2026 net income of $26.6 million. The thesis depends on banking software demand, subscription durability, margin expan
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAffirm is scaling GMV and has moved into GAAP operating profitability, but the stock thesis still depends on credit discipline, funding access, partner concentration, regulation and whether Card, wallets and international expansion preserve unit economics.
OpenAI Financial has a real ALT5 fintech platform with $24.8 million of FY2025 revenue and $3.5 billion of disclosed 2025 transaction volume, but its current equity story is dominated by WLFI token volatility, a $344.5 million net loss, a working-capital deficit,
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
OpenZymeworks Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZhengye Biotechnology Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZurn Elkay Water Solutions Corporation has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZevia PBC has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZura Bio Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZumiez Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZoetis reported FY2025 revenue of $9.47 billion and Q1 2026 revenue of $2.26 billion, with the official record tying the thesis to companion-animal demand, livestock cycles, product innovation, inventory quality, debt and cash conversion.
OpenZTO Express reported 2025 revenue of CNY 49.10 billion, operating income of CNY 10.47 billion and operating cash flow of CNY 11.97 billion. The thesis turns on China parcel volume, pricing, network efficiency, cash conversion and ADR governance risk.
OpenYY Group Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Open